Sulemanjee Nasir Z, Merla Ramanna, Lick Scott D, Aunon Serena M, Taylor Melissa, Manson Melissa, Czer Lawrence S C, Schwarz Ernst R
Division of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, USA.
J Cardiovasc Pharmacol Ther. 2008 Mar;13(1):13-31. doi: 10.1177/1074248407309916.
A large number of heart transplants are performed annually in different transplant centers in the United States. This is partly because of the improved survival of patients who undergo cardiac transplantation, thus making it a more viable option in the management of end-stage heart failure. The survival benefit after heart transplantation is a result of newer immunosuppressive drug regimens and a better understanding of their effects and interactions. Several studies, mostly involving a small number of patients, describe use and comparison of the many distinct immunosuppressive drugs available to date. Interestingly, many transplant centers perform in-house typical induction treatment regimens because of their own experience and intra-institutional preference. This review summarizes current practices of immunosuppressive drug therapy in the first year post-heart transplant based on the available clinical evidence and discusses future options of heart transplant immunosuppressive drug therapies.
美国不同的移植中心每年都会进行大量的心脏移植手术。部分原因是接受心脏移植患者的生存率有所提高，因此在终末期心力衰竭的治疗中，心脏移植成为了一个更可行的选择。心脏移植术后的生存获益得益于更新的免疫抑制药物方案以及对其作用和相互作用的更好理解。多项研究（大多涉及少数患者）描述了目前可用的多种不同免疫抑制药物的使用和比较情况。有趣的是，许多移植中心基于自身经验和机构内部偏好，采用内部典型的诱导治疗方案。本综述基于现有临床证据总结了心脏移植术后第一年免疫抑制药物治疗的当前实践，并讨论了心脏移植免疫抑制药物治疗的未来选择。
